| Name | Title | Contact Details |
|---|
C2i Genomics is the first company to offer post-surgery monitoring of cancer recurrence and progression by analyzing subtle changes in the pattern of the tumor`s DNA. Our liquid biopsy Whole Genome assay and cancer burden score will equip oncologists with vital timely information months to years before current monitoring methods are able to.
Foresite Labs incubates companies that will address some of our greatest unmet medical needs. Their experienced team of scientists, engineers, and operators believes that the tools of data science, when applied with scientific rigor, will greatly accelerate scientific discovery and the development of new products and services that benefit patients. Through its incubation platform, Foresite Labs is dismantling the barriers faced by visionary entrepreneurs and their companies as they seek to re-invent healthcare. Foresite Labs Values Truth over progression: We follow the science, pursuing ideas that are grounded in data and abandoning them when not supported by the evidence. Take good risks: Our culture values informed risk-taking: good decisions are celebrated even when they result in bad outcomes. Everyone feels safe to contribute ideas and to learn from failure. Single accountable person: The project team lead is accountable for all decisions and for maintaining transparency and information flow within the team; we trust the project teams. The Review Committee unlocks capital and sets directions. Simplicity and Focus: Companies die from indigestion, not starvation (Bill Hewlett) We will focus on a few ideas aggressively and minimize all other distractions. Everyone will have a few key goals that have measurable outcomes. Respect and Community: Our employees are our greatest asset; everyone invests in creating an environment of collaboration and respect. We support their careers and career development whether they stay, go to a Labs company, or end up somewhere else.
At Spark Therapeutics, we don`t follow footsteps. We create the path. We were born of innovation, springing from the curiosity, imagination and dedication of remarkable scientists and healthcare visionaries. Our mission is seemingly impossible to others, but not to us: Challenge the inevitability of genetic disease by discovering, developing and delivering treatments in ways unimaginable – until now. Since our founding, we have been committed to bringing a wide range of expertise to build a fully integrated gene therapy company focused on inherited retinal diseases (IRDs), neurodegenerative diseases, as well as diseases that can be addressed by targeting the liver, such as hemophilia. We are seeking talented individuals with diverse experiences, abilities and interests who have the curiosity, courage and drive to reimagine a new health care paradigm. Join us on a journey through uncharted territory – seeking to bring gene therapy for genetic diseases to people worldwide. The resilience of the people we serve is our inspiration to break barriers, as we strive to turn genes into medicine for those with inherited diseases. Spark is a member of the Roche Group.
Vitro Biopharma, a publicly traded biotechnology firm (OTCQB:VODG), develops technology and products derived from adult stem cells and is currently focused on mesenchymal stem cells (MSCs). MSCs have numerous applications in treatment of a variety of medical conditions, including injuries or diseases of the joints, heart, kidney, liver and lung failure, MS, stroke, cancer, hearing loss, and various other regenerative medicine applications. MSCs may be derived from an individual patient, expanded and then transplanted back to that patient to treat injury or disease through regeneration or repair of specific cells. Vitro manufactures and distributes to global markets a series of products for use by scientists and companies developing clinical applications of MSCs. Our products include: a) Cell Culture Media -We offer various formulations of MSCs and primary cell cultures with numerous competitive advantages. b) Various Cell Lines -Our cell lines include Umbilical Cord Blood derived MSCs, Adipose derived MSCs, Fluorescent Labeled MSCs, Cancer Associated Fibroblasts (CAFs), and Differentiated MSCs c) Brain-Grow Technologies -Neurological and Inflammatory Biomarker Profiling and Nutraceutical Recovery Packages
Metavention is a venture-backed medical device company founded in 2012 that is developing a novel glucose control therapy for patients with type 2 diabetes. Metabolic Neuromodulation Therapy (MNT) is a simple cardiovascular procedure intended to modulate sympathetic nervous system activity in patients with Type 2 diabetes for the purpose of lowering blood glucose levels. MNT was developed based on published scientific data and extensive animal studies suggesting a link between elevated sympathetic nerve activity in the metabolic system and increased levels of blood glucose. MNT is currently being studied in human clinical trials and represents a potentially important new treatment option for patients with Type 2 Diabetes.